Appclon and Turkey's TCT to Collaborate on Joint CAR-T Development

Expanding Collaboration on zCAR-T 'AT501' for Solid Tumors and In Vivo CAR-T Development

Appclon is advancing joint development cooperation with its Turkish partner, TCT Health Technologies, for a range of cell therapies from blood cancer CAR-T therapeutics to next-generation cell therapy products.

On the 25th, at the GMP center located in Antalya, Turkey, AppClone CEO Jongseo Lee (far left) and TCT President Erkan Mankan (far right) took a commemorative photo after signing a memorandum of understanding (MOU) for comprehensive cooperation on next-generation pipelines. AppClone

Appclon announced on the 29th that CEO Jongseo Lee visited the TCT headquarters in Istanbul, Turkey on the 25th and signed a memorandum of understanding (MOU) for the development of next-generation cell therapies.

The main focus of this partnership is to accelerate the clinical development of Appclon's CD19-targeting CAR-T therapy candidate, AT101, in Turkey. Appclon is currently in the final stages of patient recruitment for its Phase 2 clinical trial in Korea, and discussed with TCT ways to shorten the clinical trial timeline in Turkey through cooperative measures.

AT101 is a CAR-T therapy candidate under development for B-cell lineage hematologic malignancies. Appclon completed a technology transfer of AT101 to TCT in March last year, and through this collaboration, aims to expand its local clinical and commercialization foundation.

The two companies plan to expand their cooperation beyond blood cancer therapies to the development of next-generation CAR-T treatments for solid tumors. They will focus on breast cancer and other solid tumor therapies based on Appclon's switchable CAR-T (zCAR-T) platform, AT501, and intend to broaden their joint development efforts into the in vivo CAR-T field as well.

Additionally, representatives from Appclon and TCT visited Akdeniz University's clinical and CAR-T manufacturing facilities in Antalya, Turkey, to review their research and production infrastructure. The two companies plan to utilize these facilities for the joint clinical development of next-generation CAR-T candidates in the future.

CEO Lee stated, "Based on our cooperation for the clinical development of AT101, we are expanding the scope of collaboration to include solid tumor therapies and the in vivo CAR-T field," adding, "We will leverage Turkey's clinical and manufacturing infrastructure to strengthen our foundation for global market entry."

This content was produced with the assistance of AI translation services.